The rapid development of endothelin-receptor antagonists has made the endothelin pathway a new therapeutic target in the treatment of cardiovascular diseases, only ten years after the report of its discovery. While the first clinical trials will help to position this new family of compounds in our therapeutic armament for the treatment of essential or secondary forms of hypertension, several preclinical chronic studies already provide a picture of what we can expect from these drugs. Endothelin-receptor antagonists are not effective in all experimental models of hypertension, but those that respond present hypertrophy of small arteries, secondary to a local overexpression of the peptide. Although angiotensin II seems to represent a stimulus for endothelin overexpression in some models, other, as yet undetermined, stimuli are likely in others. Besides their narrow spectrum of antihypertensive activity, endothelin-receptor antagonists may also protect from complications of hypertension by improving end-organ function in a pressure-independent manner. This seems to be the case for the structure and reactivity of resistance arteries, as well as for renal damage. However, it is not clear at this point if cardiac structure and function are improved beyond the benefits produced by blood pressure reduction. The first results in essential hypertensive subjects suggest some degree of efficacy of endothelin-receptor antagonists. Other clinical trials will help to determine if secondary forms of the disease benefit equally or more from this new class of drugs, and if end-organ damage can be reduced beyond blood-pressure reduction.
Introduction
hypertensive cardiovascular system. Although the biology of ET is interesting on its own, it is the subject of several Endothelin (ET)-1 is recognized as an important local good reviews [4] [5] [6] and will not be discussed in detail. The modulator of vascular function. During the ten years that development of endothelin antagonists has also been elapsed since the publication of its discovery, [1] sustained reviewed appropriately in recent articles [6, 7] . This short efforts both by the scientific community and the pharmareview will present the experimental observations obtained ceutical industry have promoted the ET pathway as a new with ET-receptor antagonists in several models of hytherapeutic target in cardiovascular diseases. Endothelin, pertension and in man, focusing on their blood pressure an endothelium-derived 21 amino-acid peptide, is the most lowering efficacy and their potential to limit hypertensionpotent vasoconstrictor known, working at nanomolar coninduced end-organ damage. centrations [2] . It is also a trophic factor and a mitogen, two additional properties that are of interest considering the trend to improve end-organ remodeling in addition to 2. Antihypertensive efficacy in experimental and normalize arterial pressure, in the treatment of hypertenessential hypertension sion. Now that the industrial race is on and several clinical trials are under way to determine the clinical benefits of Before the advent of ET-receptor antagonists, several ET-receptor blockade [3] , it seems appropriate to review lines of evidence supported the candidacy of ET as a the data pertaining to the involvement of ET in the hypertensive factor. Indeed, ET is a powerful vasoconstrictor and, even at preconstricting levels (picomolar con-centrations), it enhances the response to other vasoconstricveloped were rapidly tested in models of hypertension. tors [8, 9] . These observations suggest that subtle changes Accordingly, Nishikibe et al. [18] observed a reduction in of its local concentrations could have profound effects on arterial pressure in stroke-prone spontaneously hypertenvascular tone. In addition, ET can influence the carsive rats (SHR-SP), but not in SHR after acute administradiovascular system more permanently by altering the tion of a selective ET -receptor antagonist. The group at A cardiovascular structure through its mitogenic [10] and Hoffmann-LaRoche also reported an acute antihypertentrophic [11] effects. Moreover, administration of exogensive efficacy of their compound in salt-depleted squirrel ous ET is hypertensive in rats [12] and dogs [13] , and monkeys [19] , leading the way to chronic studies with patients with hemangioendothelioma (characterized by ET-receptor antagonists in several animal models of high circulating levels of ET) have hypertension [14] . On hypertension with different pathological features (Table 1) . the other hand, circulating levels of the peptide (although A blood pressure reduction can be observed when hynot a good indication of the activity of the system) are pertension is induced by increasing circulating angiotensin normally not elevated in hypertensive patients [15, 16] , (Ang) II levels to that found in early 2-kidney / 1-clip arguing against the involvement of ET in human hyperten-(2K / 1C) hypertensive rats [20] with a subcutaneous sion. Furthermore, the vascular responses to ET are administration of an initially subpressor dose of the peptide generally blunted in arteries from hypertensive animals [21] . Endothelin-receptor antagonists are also effective in (Table 2 ) and in patients [17] . These observations repreDahl salt-sensitive rats fed a high salt diet [23] , and sent indirect approaches to determine the role of ET in demonstrated a modest efficacy in deoxycorticosterone hypertension and the advent of ET-receptor antagonists acetate (DOCA)-salt hypertensive rats [24, 25] . All three provided the tools to address that question more convincmodels have vascular overexpression of ET [21, 26, 27] , ingly.
and this represents a common pathological feature that Thus, it is no surprise that the first antagonists decould explain the antihypertensive efficacy. Ang II has Table 1 Efficacy of chronic treatments with ET-receptor antagonists to reduce arterial pressure, vascular cross-sectional area (CSA) and heart weight / body weight ratio (HW/ BW) in common experimental models of hypertension been recognized as a stimulus for ET production in vitro was due to ET [39] [40] [41] . These acute studies confirmed the [8, 28] , and we recently confirmed that this occurs in vivo functional inhibition of ET by NO that was previously in the vasculature as well [21] . Since renin angiotensin demonstrated in vitro [42] . However, at least two chronic system (RAS) activity is blunted in DOCA-salt hypertenstudies in rats failed to confirm any significant long-term sive rats, and most likely in Dahl rats fed a high salt diet, involvement of ET in L-NAME-induced hypertension other factors may also trigger the exaggerated production [43, 44] . Furthermore, the levels of the peptide in the vessel of ET. Besides Ang II, no other candidates have been put wall of small arteries do not seem to be enhanced in forward, but, based on in vitro cell culture experiments, the animals with chronic NO deprivation [44, 45] , in line with list of putative candidates includes hypoxia, thrombin, the lack of antihypertensive responsiveness. TGF-b, IGF, interleukin-1, catecholamines, cortisol and Judging from the preclinical data published so far, the vasopressin, to name a few [2, 4] . selectivity of the antagonist does not appear to be critical, Chronic administration of an ET-receptor antagonist is considering that both ET -selective and non-selective A unable to lower arterial pressure in renovascular models of ET -receptor antagonists are effective in Ang II [22, 46] ,
hypertension [29] . In the 1K / 1C model, there is hy-SHR-SP [37, 38] and DOCA-salt hypertension [24, 35] , and pertrophy and significant overexpression of ET in small ineffective in SHR [34, 35] , 1K / 1C [29, 35] and L-NAME arteries [30] . However, the lack of responsiveness to ET- [43, 44] models. receptor antagonists is surprising, especially if one considIt also appears quite clear that ET-receptor antagonists ers that treatment was initiated at the same time as the clip are not ubiquitous antihypertensives, as more classical was installed on the remaining kidney [29] . As suggested therapeutic agents appear to be. No definitive pattern of by the authors, the increases in local ET production may be efficacy can be drawn at this point, except that models in too modest for a marked pathophysiological involvement which ET-receptor antagonists are effective show a vascu- [29] . In 2K / 1C hypertensive rats, vascular hypertrophy lar overexpression of the peptide (Table 1) . Although and small artery ET expression are not really enhanced initial results indicated that ET was involved only in severe [30] , explaining the lack of responsiveness to the antagoforms of hypertension, the results in the low-dose Ang II nists [29] . Interestingly, ET overexpression in small armodel, which has a moderate increase in blood pressure, teries was inversely related to plasma renin activity suggest otherwise [21, 22, 46] . The local interplay between measurements, suggesting that models of low RAS activity Ang II and ET may therefore represent a significant may have greater endothelial ET expression [30] . It must determinant of responsiveness to ET-receptor antagonists, be pointed out, however, that plasma renin activity and and it is of interest that captopril reduced plasma ET levels even plasma Ang II levels may not reflect the activity of in hypertensive but not in normotensive subjects [47] . the local vascular RAS. Accordingly, Lariviere recently Salt-sensitivity and salt loading also seem to be of imporshowed, in a remnant kidney model of hypertension (with tance and may represent another trigger for ET overexpreslow circulating Ang II levels) submitted to different sion, considering the results obtained in DOCA-salt and pharmacological interventions, that vascular concentrations salt-loaded Dahl salt-sensitive rats (Table 1) . of ET were directly related to Ang II concentrations in the Obviously, the definitive answer to the therapeutic use same tissues, but inversely related to plasma Ang II levels of ET-receptor antagonists will come from clinical trials. (Lariviere 1998, personal communication) . These results So far, one study in essential hypertensive patients, support a strong local relationship between Ang II and ET compared the antihypertensive efficacy of a non-selective at the tissue level. Furthermore, many reports also suggest ET-receptor antagonist with that of an angiotensin-converta dissociation between the circulating and local RAS ing enzyme (ACE) inhibitor and placebo [48] . With an activity in renovascular hypertension [31, 32] , and heteroappropriate dosage (500 mg daily or more), four weeks of geneity between tissues in the same animals [33] . Simultatreatment with the antagonist proved to be as effective as neous evaluation of tissue concentrations of Ang II and ET 20 mg of enalapril. However, 500 mg already produced the may therefore represent a desirable approach to verify the maximal efficacy and further increments in dosage (up to interaction between the two peptides.
2000 mg daily) did not bring diastolic pressure to norLi and Schiffrin [34] reported that ET is not overmotensive values. Indeed, pretreatment diastolic pressure expressed in the vessel wall of SHR, making the peptide an in the treated groups varied between 101 to 107 mmHg unlikely participant in the pathophysiological process in and the antagonist produced a maximal reduction of 6 this genetic model. Accordingly, SHR are clearly resistant mmHg, well above normotension. Nevertheless, these to the antihypertensive effect of ET-receptor antagonists results do suggest a role of ET in essential hypertension. [34] [35] [36] . In sharp contrast, salt-loaded [37] or control [38] This seems to contradict what has been suggested from SHR-SP have increased circulating levels of ET [18] , preclinical studies in which vascular hypertrophy and local probably coming from increased endothelial production, overexpression of ET predicted the antihypertensive efficaand do respond to the antagonists. cy (Table 1) . It is indeed interesting to note that small In the L-NAME model, acute in vivo studies suggested arteries of mild essential hypertensives are characterized that a significant part of the pressor effect of NO inhibition by eutrophic remodeling [49] without overexpression of the peptide [50] . This apparent discrepancy between rat small arteries (,300 mm) adapt their structure to normalmodels and man is further emphasized by the reduction of ize wall stress, by increasing the media thickness-to-lumen arterial pressure in normal subjects after the acute adminisdiameter ratio (M /L) [49] . A nomenclature for all possitration of an ET-receptor antagonist [51] , an effect that is bilities to obtain such an increased ratio has been put seldom seen in normotensive animals. In addition, the first forward by several investigators [56] . The term eutrophic clinical trials in patients with congestive heart failure inward remodeling has been coined for a change in M /L reported a pressure reduction of 10-15 mmHg, making without an actual change in tissue content (or crosshypotension a major side effect [3, 52] . Future studies will sectional area, CSA). This necessarily implies that the help to determine if ET exerts a more significant control of content of the vessel wall is rearranged (with or without blood pressure in man than in animal models. cellular turnover) around a smaller lumen diameter. This type of remodeling seems to occur in several models of hypertension [49] , including the L-NAME model (Fig. 1)  3 . Protection of end-organs [57] , and in essential hypertension [49] . Hypertrophic remodeling (outward or not) represents another process in In addition to lower arterial pressure, new antihyperwhich the lumen diameter is not necessarily modified, but tensive agents are developed to protect target organs from the surface area of the vessel wall (CSA) is clearly the deleterious effect of chronic pressure elevation. These enhanced, again in an effort to normalize wall stress by may include tissue hypertrophy, capillary rarefaction and increasing M /L. This process is found in Ang II-induced perfusion restrictions, all leading to a progressive loss of hypertension ( Fig. 1) [21,58], in some secondary forms of function of vital organs. Although increased vascular tone human hypertension [59] as well as in severe human may be involved in these processes, more permanent hypertension [50] . The initial influences that determine the changes are brought by remodeling of the vasculature.
type of remodeling (eutrophic vs. hypertrophic) are not Accordingly, besides being a potent vasoconstrictor, ET known, but ET overexpression may participate at some has been shown to be mitogenic [10] and trophic [11, 53] point (see below). on cultured cell systems derived from cardiovascular
If one looks at small arteries in a hypertensive context, tissues. It is not clear which effect predominates in vivo, circumferential wall stress is generally normal, due to the but a study in serum-free primary cultures suggests that ET increased M /L, as discussed above. When blood pressure is is a trophic factor, with poor mitogenic activity [11] . Thus, brought to lower levels, M /L will again change to normal-ET has the potential to be involved in hypertrophy, ize wall stress, so that there always exist a strong relationalthough it may also modify cell number by inhibiting ship between M /L and arterial pressure at, least in animals apoptosis, as suggested by some recent reports [54, 55] .
( Fig. 1) . However, there is a clear dissociation between CSA changes and those of blood pressure and M /L (Fig.  3.1 . Remodeling of resistance arteries 1). As an example, two weeks of Ang II or L-NAME treatments produced similar increases in pressure with When submitted to a sustained increase in pressure, similar M /L of basilar arteries. However, CSA increased only in the Ang II group, indicating an increased amount striction, especially if vascular tissues were more sensitive of material in the vessel wall (Fig. 1) . Thus, vascular to its action. In contrast, however, most forms of exhypertrophic remodeling has a pressure-independent comperimental hypertension, such as SHR, L-NAME [57, 60] , ponent. This was already suggested some years ago when DOCA-salt [61] and Ang II [46] , as well as essential normalization of blood pressure in Ang II-treated rats by hypertensive subjects [17] , show a reduced maximum hydralazine failed to normalize CSA [58] . We recently contraction to ET. This may not be true for all vascular demonstrated that ET-receptor blockade prevented totally beds, and the renal circulation may represent a notable Ang II-induced hypertrophic remodeling, without norexception, considering its long-term role in pressure regumalizing arterial pressure ( Fig. 1 Table 1 ), suggesting that lation and its high sensitivity to the vasoconstrictor effect endogenous ET is responsible for increased vascular CSA, of ET [62] . Indeed, in the SHR, the vasoconstrictor independently of arterial pressure [21] .
responses to ET are maintained [63] or even increased Even more striking are the results found in Dahl salt- [64] . Furthermore, in human hypertensive subjects, the sensitive animals fed a high sodium diet. In the same renal vascular effects of exogenous ET administration are animals, basilar arteries showed characteristic signs of not blunted [65] . eutrophic remodeling (increased M /L ratio without inSome of the published effects of chronic treatments with creased CSA), while mesenteric resistance arteries had ET-receptor antagonists on vascular reactivity are summaincreased CSA (Fig. 2) . Chronic administration of an rized in Table 2 . Most of the pathological changes that ET -receptor antagonist normalized the CSA of mesenteric were observed in the untreated hypertensive animals were A arteries, without altering that of cerebral arteries. The improved by these antagonists. It is the case for those that reduction of the M /L ratio followed changes in arterial respond to the antihypertensive and hypotrophic effects of pressure. These observation again confirm the involvement the antagonists [23, 24, 27] , but also for L-NAME-treated of ET in hypertrophic, but not in eutrophic, remodeling, a rats, which are resistant [43] . Thus, this effect does not conclusion shared by Chillon et al. [38] who studied seem to be pressure-dependent or even secondary to cerebral arterioles in SHR-SP. In fact, all models studied so improvement of vascular structure. Of special interest is far in which increased tissular ET levels have been the amelioration of ET-1-induced contractions by receptor reported also show some degree of vascular hypertrophy.
antagonists in most models (Table 2) , despite ET overInterestingly, ET-receptor antagonists are able to lower expression (and possible receptor down-regulation) in arterial pressure significantly in these models, except in some models only. The reason for the normalization of 1K / 1C animals displaying a modest increase in vascular vascular function in terms of responsiveness to vasocon-ET levels (Table 1) 
The arrows depict the changes observed in untreated hypertensive rats compared to normotensive controls, and in rats treated chronically with an ET-receptor antagonist compared to untreated hypertensive rats. Thus, arrows in opposite directions between the two situations denote an improvement. Ach, acetylcholine; SNP, sodium nitroprusside; Ang II, angiotensin II; ET-1, endothelin-1; NE, norepinephrin; 5-HT, serotonin; ↑, increase; ↓, decrease; ↔, no change.
prostacyclin release [66] . This is especially true if one Accordingly, overexpression of ET seems to be limited to considers the enhanced levels of ET that are normally endothelial cells of coronary vessels and the endocardium, observed with the chronic administration of selective or and not in the myocardium [69] . In the SHR, a model non-selective ET-receptor antagonists [46, 52] . So far, resistant to ET-receptor antagonists in terms of pressure however, very few direct comparisons of both types of reduction, Karam et al. [36] could observe a small reducantagonists have been made with respect to endotheliumtion in left ventricular area / body weight ratio (7%, p, dependent relaxation. We recently obtained results showing 0.05), but no overt improvement of heart weight / body a pressure-independent improvement of endothelium-deweight or left ventricular weight / body weight ratios. In pendent vasorelaxation with an ET -receptor antagonist in SHR-SP, the reduction in blood pressure was accompanied A L-NAME-induced hypertension [67], while our previous by reduced cardiac hypertrophy [37] . Overall, the instudy with a non-selective antagonist showed no improveformation available would suggest that, although ET may ment of the relaxations in the same model (Table 2 ) [43] .
have a focal role in cardiac fibrosis, hemodynamic factors, In DOCA-salt hypertensive rats, the use of a non-selective such as arterial pressure per se, may prove to be more antagonist did not improve the endothelial function [24] . In essential in cardiac hypertrophy. contrast, an ET -receptor antagonist improved endothelial Another significant finding is that the maximal coronary A function both in the aorta [27] and mesenteric resistance blood flow was not improved by chronic ET-receptor arteries [23] of Dahl salt-sensitive rats (Table 2) . However, antagonism in SHR and DOCA-salt hypertensive rats no direct comparison was made with the other type of [25, 36] . In the DOCA-salt model, this seems to contradict antagonist in these two models.
the improvement of vascular structure [24] . It must be pointed out, however, that hypertrophic remodeling (in-3.3. Left ventricular hypertrophy and cardiac function creased CSA without reduction in lumen diameter), such as seen in this model, may not limit blood flow in maximally The in vivo trophic effect of ET seems to be confirmed dilated arteries, but it may allow the vessels to contract in by the ability of ET-receptor antagonists to prevent cardiac an exaggerated fashion in response to agonists in more hypertrophy in Ang II-induced hypertension (Table 1) physiological conditions [70] . [22] . A major role for ET has also been suggested in A recent study reported a deleterious involvement of ET NE-induced cardiac hypertrophy, where a transient ET (and benefits from ET-receptor antagonism) in cardiac overexpression was documented [68] . However, the results remodeling following myocardial infarction. Indeed, after obtained in the DOCA-salt model are less striking. Indeed, eight weeks of treatment (but not after the first week) with one study failed to show prevention of cardiac hypertrophy an ET-receptor antagonist, there were significant reduc- [24] , while another one, using the same antagonist, retions in left ventricular dilatation and improvements of ported a reduction in left ventricular area and thickness, heart performance [71] . This observation, together with the without significant reduction in left ventricular weight earlier report of acute effectiveness of ET-receptor antago- [25] . It is remarkable, however, that perivascular and nists in human chronic heart failure [52] , suggests a subendocardial fibrosis were significantly improved by beneficial role of ET-receptor antagonists in the long-term chronic ET-receptor antagonism in these animals [25] .
cardiac complications of hypertension.
3.4.
Renal function ET-receptor antagonists seems promising for kidney protection in the context of hypertension or not. ApproRenal effects of ET may also include cellular proliferpriate studies in man will help to determine the therapeutic ation and vasoconstriction [72] . Interestingly, the renal role of ET-receptor antagonists in renal disease and in the vasculature is highly sensitive to the vasoconstrictor action prevention of hypertension-induced renal damage, and the of ET that takes place both at the pre-and postglomerular type of antagonist most helpful in these conditions [72] level [72] . Indeed, subpressor doses of the peptide have a (see also a review on the subject in this issue). marked effect on renal hemodynamics in man [73, 74] . In addition to its hemodynamic effects, ET also inhibits medullary sodium and water reabsorption in certain con-4. Conclusion and perspectives ditions, such as ischemia [75] . However, the physiological significance of these observations seems to be limited in During the last few years, the availability of ET-receptor animals, since ET-receptor antagonists do not have a antagonists has generated a lot of information on the marked effect on normal kidney function [72] . The repathophysiological role of ET in preclinical models of ceptor subtypes involved in these different actions of ET hypertension. However, it is not clear by which mechanism may also be variable between species, and extrapolations ET influences blood pressure in most models. Direct should be made with caution [72] . In SHR, blood pressure vasoconstriction does not appear to be the most likely is not affected by ET-receptor antagonists, but a nonmechanism, if one considers the general blunted vascular selective ET-receptor antagonist was more effective than a responsiveness in hypertensive animals and in man. Amcalcium channel blocker or an ACE inhibitor at improving plification of constriction by other agonists seems more creatinine clearance [36] . Similarly, ET-receptor antagolikely, especially if one considers the strong influence of nists were able to improve renal vascular injuries (in-ET on vascular structure, which may also contribute to the flammatory and proliferative) in the L-NAME model, enhancement of vascular responsiveness. Although the without altering the state of hypertension [76] . In Dahl antagonists may reduce kidney damage and lower arterial salt-sensitive animals, local administration of an ET-repressure in renal failure models, the positive renal effects ceptor antagonist, which did not show any systemic effect, in hypertensive models were not associated with blood improved renal hemodynamics and excretory functions pressure reduction. However, it is possible that improved [77] . Overall, there may be beneficial effects of ETrenal function participates in the pressure reduction in receptor blockade in limiting hypertension-induced kidney models that are responsive to ET-receptor antagonists. damage, despite poor efficacy to lower arterial pressure.
What seems rather clear, however, is that ET-receptor Convincing evidence exists to show that ET-receptor antagonists are not ubiquitous antihypertensives in animal antagonists can alleviate acute renal failure in animal models. The responsive models have vascular overexpresmodels (for reviews, see [6, 72] ). The pathological process sion of the peptide and hypertrophic remodeling of armost likely involves renal vasoconstriction, leading to teries. In contrast, the first results obtained in man seem to ischemic necrosis of renal tubules [78] . ET seems to be a suggest a moderate efficacy of the antagonists in essential major player in this process, and its antagonists may prove hypertension, which does not show vascular overexpresto be therapeutically meaningful. ET-receptor antagonists sion of ET. Therefore, the identification of the patient may also be of therapeutic use in the prevention of the profile responsive to ET-receptor antagonists will be of development of chronic renal failure, and this is parmajor interest during the next few years. In addition, the ticularly significant in the context of hypertension. Indeed, (dis)agreement of the clinical trials with the preclinical ET has the potential to be partly responsible for the results summarized above will provide a critical evaluation glomerular hypertension and hyperfiltration, mesangial cell of the validity of several of our animal models of hypertenproliferation and extracellular matrix production that have sion to predict the efficacy of new antihypertensive stratebeen observed during the progression of the disease [6] .
gies. Finally, end-organ protection may represent an Accordingly, ET overexpression seems to be limited to important asset of ET-receptor antagonists, hopefully preglomerular arteries and to glomeruli in rats with releading to a reduction in cardiovascular morbidity and duced renal mass [79] . In addition, ET gene expression mortality beyond what is currently achieved with available correlates well with the progression of the disease [80] , therapies. and ET-receptor antagonists protect the kidney in animal models of chronic renal failure [81] . Moreover, in these experimental models, ET-receptor antagonists reduce arAcknowledgements terial pressure, suggesting a substantial role of ET in elevation of blood pressure during the disease process [81] .
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